loading page

A study of the efficacy and safety of plaque psoriasis treatment by TNF- α and IL-17A inhibitor biologics in patients who received the inactivated SARS-CoV-2 vaccine
  • +3
  • Shuhong YE,
  • SUN Hong,
  • WU Jiawen,
  • XU Zining,
  • XU Bingyang,
  • Na WU
Shuhong YE
Xi'an Jiaotong University Second Affiliated Hospital
Author Profile
SUN Hong
Xi'an Jiaotong University Second Affiliated Hospital
Author Profile
WU Jiawen
Xi'an Jiaotong University Second Affiliated Hospital

Corresponding Author:[email protected]

Author Profile
XU Zining
Xi'an Jiaotong University Second Affiliated Hospital
Author Profile
XU Bingyang
Xi'an Jiaotong University Second Affiliated Hospital
Author Profile
Na WU
Xi'an Jiaotong University School of Medicine
Author Profile

Abstract

ABSTRACT: Backgr ound : Vaccination is an important method for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission. There is currently a lack of real-world clinical data regarding the safety and efficacy of coronavirus disease 2019 (COVID- 19) vaccines with respect to plaque psoriasis treatment involving tumor necrosis factor (TNF)-α and interleukin (IL)- 17A inhibitors. Method s: We longitudinally analyzed 152 patients with plaque psoriasis, 86 of whom received two doses of inactivated COVID- 19 vaccine (either BBIBP-CorV or CoronaVac). Comparisons were made between patients undergoing treatment with biologics (TNF- α inhibitors or IL- 17A inhibitors) or acitretin. Routine blood tests were used to assess safety; the psoriasis area and severity index (PASI) and dermatology life quality index (DLQI) were used to assess efficacy. Results: After inactivated COVID- 19 vaccination, biologics retained considerable advantages in terms of improving skin lesions (measured by PASI) and quality of life (measured by DLQI), compared with conventional treatment (p<0.05 and p<0.01, respectively). Routine blood tests and hepatorenal function analyses suggested that inactivated SARS-CoV-2 vaccines did not alter the safety of biologics treatment (p>0.05). Conclusions: Inactivated SARS-CoV-2 vaccines do not have significant impacts on the safety and efficacy of biologics (TNF-α inhibitors or IL- 17A inhibitors) in patients with moderate to severe plaque psoriasis.
14 Jan 2023Submitted to Immunity, Inflammation and Disease
18 Jan 2023Submission Checks Completed
18 Jan 2023Assigned to Editor
18 Jan 2023Review(s) Completed, Editorial Evaluation Pending
29 Jan 2023Reviewer(s) Assigned
11 Mar 2023Editorial Decision: Revise Major
27 Apr 20231st Revision Received
02 May 2023Submission Checks Completed
02 May 2023Assigned to Editor
02 May 2023Review(s) Completed, Editorial Evaluation Pending
03 May 2023Reviewer(s) Assigned
25 Jun 2023Editorial Decision: Accept